NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Universe Pharmaceuticals INC (UPC) Stock Analysis

Universe Pharmaceuticals INC (UPC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

UPC

$4.19

+$0.64 (+18.03%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare UPC with… →

UPC Key Statistics

As of Oct 21, 2026
Trading
Open
$3.62
Previous Close
$3.55
Day's Range
3.54–4.28
52-Week Range
2.00–17.96
Volume
227.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.68
Valuation
Market Cap
$21.05M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.19
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.26
Financials (FY)
Revenue (FY)
$17.86M−22.44%
Net Income (FY)
−$3.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.95%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.01M
1-Year Return
−20.19%
Dividend and dates
Avg Volume
771.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, UPC closed at $4.19, −20.19% over 1 year.

Universe Pharmaceuticals INC (UPC) has a market capitalization of $21.05M.

In fiscal 2025, UPC reported revenue of $17.86M.

UPC Stock Return by Calendar Year

Universe Pharmaceuticals INC (UPC) return since Mar 2021: what $10,000 became

1 year
$10,000 $7,981
−20.19%
5 years
$10,000 $5
−99.95%
Since Mar 2021
$10,000 $2
−99.98%

If you had invested $10,000 in Universe Pharmaceuticals INC (UPC) at the close on March 23, 2021, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −77.46% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.97%
2025−84.39%
2024−97.98%
2023−76.90%
2022−11.31%
2021 (partial year)−65.58%

As of October 21, 2026.

UPC Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$17.86M−$3.67M−20.6%
2024$23.02M−$8.73M−37.9%
2023$32.31M−$6.58M−20.4%
2022$40.14M−$7.91M−19.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$17.86M$6.30M−$2.92M−$3.67M−20.6%
2024$23.02M$6.07M−$8.02M−$8.73M−37.9%
2023$32.31M$10.32M−$3.97M−$6.58M−20.4%
2022$40.14M$21.89M−$7.02M−$7.91M−19.7%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

UPC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricUPCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.192.1043% below
Profit margin−10.95%−8.14%2.8 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Universe Pharmaceuticals INC (UPC) at $21.05M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 216.

Over the past 52 weeks the price has ranged from $2.00 to $17.96. UPC last closed at $4.19 on October 21, 2026. That is +$0.64 (+18.03%) against the previous close. The latest close sits 109.49% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $17.86M. Against the prior fiscal year total of $23.02M, that is a change of −22.44%. The same year closed with a net loss of $3.67M. Profit margin runs at −10.95%. That is 2.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −1.26.

Across the 4 fiscal years on file, revenue moves from $40.14M in 2022 to $17.86M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.19 times revenue. On price-to-sales that is 43.5% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −20.19%. Across 5 years the annualized return works out at −78.16%. The reported beta is 1.68. Annualized volatility over the trailing 5 years is 226.29%.

Growth & Income

No dividend is on file for UPC.

2026 is still running; the total return is +9.97% year to date. The strongest complete calendar year on file is 2022 at −11.31%; the weakest is 2024 at −97.98%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Universe Pharmaceuticals INC (UPC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Universe Pharmaceuticals INC UPC $21.05M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Universe Pharmaceuticals INC has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Visit website →